Education
About Us
Working with TipRanks
Follow Us
BillionToOne, Inc. Class A (BLLN)
NASDAQ:BLLN
BLLN Stock Chart & Stats
$72.10
--
Market closed
$72.10
--
Day’s Range― - ―
52-Week Range$66.00 - $138.70
Previous CloseN/A
VolumeN/A
Average Volume (3M)218.30K
Market Cap
$3.81B
Enterprise Value$3.22B
Total Cash (Recent Filing)$195.15M
Total Debt (Recent Filing)$108.14M
Price to Earnings (P/E)808.2
Beta0.16
Next Earnings
Dec 15, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.11
Shares Outstanding41,216,110
10 Day Avg. Volume309,637
30 Day Avg. Volume218,303
Financial Highlights & Ratios
PEG Ratio2.36
Price to Book (P/B)29.04
Price to Sales (P/S)31.93
P/FCF Ratio-104.15
Enterprise Value/Market Cap0.85
Enterprise Value/Revenue12.66
Enterprise Value/Gross Profit19.42
Enterprise Value/Ebitda-2.06K
Forecast
1Y Price Target
$131.67Price Target Upside82.62% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)0.24
Revenue Forecast (FY)$405.05M
Bulls Say, Bears Say
Bulls Say
Rapid Revenue Growth And ScaleThe company has demonstrated sustained top-line expansion and volume scale, with multi-year revenue growth and a rising annualized run-rate. Such scale supports fixed-cost absorption, broader commercial penetration, and a structural path to profitability if growth sustains and unit economics hold.
Material Gross Margin ExpansionLarge margin improvements reflect higher ASPs and lower cost per test, indicating improving unit economics. Sustained high gross margins provide cushion for SG&A investments and make durable operating profitability more achievable as volumes scale and the product mix optimizes.
Strengthened Balance Sheet And Lower LeverageSignificantly reduced leverage and a larger equity base improve financial flexibility to fund sales expansion and EMR integration without immediate refinancing. A stronger balance sheet lowers solvency risk and supports multi-quarter investment in commercialization and product development.
Bears Say
Persistent Negative Operating And Free Cash FlowDespite revenue gains, the business remains cash consumptive, requiring capital to fund operations and growth. Continued negative OCF/FCF pressures liquidity and may necessitate further equity or debt funding, diluting returns or increasing leverage if cash burn does not trend toward sustained breakeven.
Ongoing Net Losses And Negative Returns On EquityThe company remains unprofitable on a net-income basis and delivers negative ROE, indicating shareholder capital is not yet earning positive returns. Without durable margin and cash-flow improvements, cumulative losses could hinder reinvestment and shareholder value creation over the medium term.
Reimbursement, EMR Investment Needs, And Negative Mix ShiftStructural risks include lower-margin oncology mix outpacing higher-margin prenatal tests, substantial EMR integration costs to win health-system volumes, and uncertain payer coverage for oncology. These factors can compress margins and slow sustainable commercial adoption if unresolved.
BillionToOne, Inc. Class A News
BLLN FAQ
What was BillionToOne, Inc. Class A’s price range in the past 12 months?
BillionToOne, Inc. Class A lowest stock price was $66.00 and its highest was $138.70 in the past 12 months.
What is BillionToOne, Inc. Class A’s market cap?
BillionToOne, Inc. Class A’s market cap is $3.81B.
When is BillionToOne, Inc. Class A’s upcoming earnings report date?
BillionToOne, Inc. Class A’s upcoming earnings report date is Dec 15, 2026 which is in 284 days.
How were BillionToOne, Inc. Class A’s earnings last quarter?
BillionToOne, Inc. Class A released its earnings results on Mar 04, 2026. The company reported $0.11 earnings per share for the quarter, beating the consensus estimate of $0.06 by $0.05.
Is BillionToOne, Inc. Class A overvalued?
According to Wall Street analysts BillionToOne, Inc. Class A’s price is currently Undervalued.
Does BillionToOne, Inc. Class A pay dividends?
BillionToOne, Inc. Class A does not currently pay dividends.
What is BillionToOne, Inc. Class A’s EPS estimate?
BillionToOne, Inc. Class A’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does BillionToOne, Inc. Class A have?
BillionToOne, Inc. Class A has 41,216,110 shares outstanding.
What happened to BillionToOne, Inc. Class A’s price movement after its last earnings report?
BillionToOne, Inc. Class A reported an EPS of $0.11 in its last earnings report, beating expectations of $0.06. Following the earnings report the stock price went down -10.714%.
Which hedge fund is a major shareholder of BillionToOne, Inc. Class A?
Currently, no hedge funds are holding shares in BLLN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
BillionToOne, Inc. Class A Stock Smart Score
Company Description
BillionToOne, Inc. Class A
BillionToOne, Inc., a precision diagnostics company, quantifies biology to create molecular diagnostics. The company provides molecular counting platform, which is designed to detect and measure DNA molecules at the single-count level to help enhance disease detection. It offers UNITY Complete, a non-invasive prenatal screen that assesses fetal risk for aneuploidies, recessive conditions, and fetal antigens from a maternal blood draw; Northstar Select, a liquid biopsy test that provides a list of mutations that are present in the tumor and types of mutations detected that include deletions, insertions, and point mutations; and Northstar Response, a test that provides longitudinal determination of cancer burden through methylation assessment. The company was incorporated in 2016 and is headquartered in Menlo Park, California.
BLLN Company Deck
BLLN Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
BillionToOne's first earnings call as a public company highlighted strong revenue growth, successful IPO, and robust gross margins. Despite challenges such as negative mix shifts and the need for further investment in EMR, the company's significant achievements and strong market position reflect a positive outlook.View all BLLN earnings summariesBLLN Stock 12 Month Forecast
Average Price Target
$131.67
▲(82.62% Upside)
Ownership Overview
34.77% Insiders
4.06%
Mutual Funds
12.15% Other Institutional Investors
48.06% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---